HomeNTRA • NASDAQ
add
Natera Inc
Previous close
$149.40
Day range
$149.14 - $153.40
Year range
$92.14 - $183.00
Market cap
20.84B USD
Avg Volume
1.43M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Revenue | 501.83M | 36.46% |
Operating expense | 395.94M | 39.95% |
Net income | -66.94M | 0.98% |
Net profit margin | -13.34 | 27.42% |
Earnings per share | -0.50 | 10.71% |
EBITDA | -69.94M | -4.00% |
Effective tax rate | -0.26% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 991.60M | 12.31% |
Total assets | 1.73B | 17.99% |
Total liabilities | 492.69M | -26.91% |
Total equity | 1.24B | — |
Shares outstanding | 136.55M | — |
Price to book | 16.38 | — |
Return on assets | -11.67% | — |
Return on capital | -14.05% | — |
Cash Flow
Net change in cash
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Net income | -66.94M | 0.98% |
Cash from operations | 44.45M | 64.63% |
Cash from investing | -16.82M | -112.16% |
Cash from financing | 544.00K | -91.59% |
Net change in cash | 28.18M | -83.59% |
Free cash flow | 17.51M | 319.87% |
About
Natera, Inc. is a clinical genetic testing company based in Austin, Texas that specializes in non-invasive, cell-free DNA testing technology, with a focus on women’s health, cancer, and organ health. Natera’s proprietary technology combines novel molecular biology techniques with a suite of bioinformatics software that allows detection down to a single molecule in a tube of blood. Natera operates CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments in San Carlos, California and Austin, Texas. Wikipedia
Founded
Jan 1, 2004
Headquarters
Website
Employees
4,429
